Polysaccharide from Fruits of Physalis Alkekengi L. Enhances Antitumor Efficacy by a DNA Vaccine
DOI:
https://doi.org/10.30564/jams.v1i4.291Abstract
Physalis. alkekengi fruit has long been used in traditional Chinese medicine for tumor therapy. In the present study, using plasmids that encode ovalbumin (OVA) gene, we investigate the adjuvant activity of a polysaccharide fraction (PPSB) isolated from P.alkekengi fruit. Formulation by simple procedures of mixing of the OVA-encoding pCI-neo-sOVA plasmid with PPSB not only induced specific antibody responses, but also induced antigen-specific cytotoxic T lymphocyte (CTL) responses (Graph abstract). Furthermore, immunization using this vaccine prevented the growth of OVA-expressing B16-OVA tumor cell growth in the immunized mice. Thus, we provide evidence supporting the adjuvant activity of PPSB in DNA vaccine against tumor.
Keywords:
Adjuvant; DNA vaccine; Physalis alkekengi L.; PolysaccharideReferences
[1] A. Stachyra, A. Gora-Sochacka, A. Sirko. DNA vaccines against influenza[J]. Acta biochimica Polonica, 2014(61):515-522.
[2] J.R. Greenland, N.L. Letvin. Chemical adjuvants for plasmid DNA vaccines[J]. Vaccine, 2007(25):3731-3741.
[3] J. Zhou, & Wang, L. Analysis of nutrient composition in the fruit of Physalis alkekengi L[J]. Journal of Nutrition, 1997(19):243-245.
[4] H. Yang, S. Han, D. Zhao, G. Wang. Adjuvant effect of polysaccharide from fruits of Physalis alkekengi L. in DNA vaccine against systemic candidiasis[J]. Carbohydr Polym, 2014(109):77-84.
[5] C.P. Committee. Pharmacopoeia of The People’s Republic of China[M]. China Medical Science Press, Beijing,2010.
[6] H. Tong, Liang, Z., & Wang, G. Structural characterization and hypoglycemicactivity of a polysaccharide isolated from the fruit of Physalis alkekengi L[J]. Carbo-hydrate Polymers, 2008(71):316-323.
[7] G. Xiao, X. Li, A. Kumar, Z. Cui. Transcutaneous DNA immunization following waxing-based hair depilation elicits both humoral and cellular immune responses, European journal of pharmaceutics and biopharmaceutics[J].Official Journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 2012(82):212-217.
[8] R. Toll, U. Jacobi, H. Richter, J. Lademann, H. Schaefer, U. Blume-Peytavi, Penetration profile of microspheres in follicular targeting of terminal hair follicles[J]. The Journal of Investigative Dermatology, 2004(123):168-176.
[9] G. Chaouat. The Th1/Th2 paradigm: still important in pregnancy?[C]. Seminars in Immunopathology, 2007(29):95-113.
[10] J. Pol, N. Bloy, F. Obrist, A. Eggermont, J. Galon, W. Herve Fridman, I. Cremer, L. Zitvogel, G. Kroemer, L. Galluzzi. Trial Watch: DNA vaccines for cancer therapy[J]. Oncoimmunology, 2014(3):e28185.
[11] S.G. Reed, S. Bertholet, R.N. Coler, M. Friede. New horizons in adjuvants for vaccine development[J]. Trends in Immunology, 2009(30):23-32.
[12] S.G. Reed, M.T. Orr, C.B. Fox. Key roles of adjuvants in modern vaccines[J]. Nature Medicine, 2013(19):1597-1608.
[13] S.P. Smeekens, M.S. Gresnigt, K.L. Becker, S.C. Cheng, S.A. Netea, L. Jacobs, T. Jansen, F.L. van de Veerdonk, D.L. Williams, L.A. Joosten, C.A. Dinarello, M.G. Netea. An anti-inflammatory property of Candida albicans beta-glucan: Induction of high levels of interleukin-1 receptor antagonist via a Dectin-1/CR3 independent mechanism[J]. Cytokine, 2014(71):215-222.
[14] D. Gordon, P. Kelley, S. Heinzel, P. Cooper, N. Petrovsky. Immunogenicity and safety of Advax, a novel polysaccharide adjuvant based on delta inulin, when formulated with hepatitis B surface antigen: A randomized controlled Phase 1 study[J]. Vaccine, 2014(32):6469-6477.
[15] P.s.C.o.A.o.S.a. Technology, Report to the President on reengineering the influenza vaccine production enterprise to meet the challenges of pandemic influenza[EB/OL].http://www.whitehouse.gov/sites/default/files/microsites/ostp/PCAST-Influenza-Vaccinology-Report.pdf, 2010.
Downloads
Issue
Article Type
License
Copyright and Licensing
The authors shall retain the copyright of their work but allow the Publisher to publish, copy, distribute, and convey the work.
Journal of Advances in Medicine Science publishes accepted manuscripts under Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0). Authors who submit their papers for publication by Journal of Advances in Medicine Science agree to have the CC BY-NC 4.0 license applied to their work, and that anyone is allowed to reuse the article or part of it free of charge for non-commercial use. As long as you follow the license terms and original source is properly cited, anyone may copy, redistribute the material in any medium or format, remix, transform, and build upon the material.
License Policy for Reuse of Third-Party Materials
If a manuscript submitted to the journal contains the materials which are held in copyright by a third-party, authors are responsible for obtaining permissions from the copyright holder to reuse or republish any previously published figures, illustrations, charts, tables, photographs, and text excerpts, etc. When submitting a manuscript, official written proof of permission must be provided and clearly stated in the cover letter.
The editorial office of the journal has the right to reject/retract articles that reuse third-party materials without permission.
Journal Policies on Data Sharing
We encourage authors to share articles published in our journal to other data platforms, but only if it is noted that it has been published in this journal.